caused by germline mutations in the CDH1 (Ecadherin) gene. Successive authors have focused on genetic causes in cancer development, particularly those that impede the repair of DNA damage. Not only germline but also missense mutations may play causative roles in carcinogenesis.
Numerous studies have examined the association between selected DNA repair gene polymorphisms and cancer susceptibility. Goode et al., 4 analyzed 30 studies focusing on polymorphisms in DNA repair genes and their role in cancer development and showed that variants of selected unique clinical and pathological features in GC patients carrying the BRCA2 polymorphism and examined a relationship between the polymorphism and risk of selected cancers in close family relatives of GC patients.
PATIENTS AND METHODS
All enrolled participants were informed about the aim and methods of the study and signed an informed consent statement reviewed by our Institutional Ethics Committee. DNA from each patient was isolated from peripheral blood leukocytes and amplified using start sites specific to the gene sequence. Subjects A total of 380 patients, diagnosed between January 1999 and December 2007 at the Department of Gastroenterology, Pomeranian Medical University, Szczecin, Poland, with histopathologically-confirmed GC, were included in this retrospective case control study. The mean age of all 380 patients (234 men and 146 women) was 59.0 ±12.8 years (range, 15-89 years). The following clinical and pathological data were collected: sex and age of the patients, family history of cancer, duration of symptoms, tumor site, stage, histology, H. pylori status, and blood group.
Control group
The control group included 380 healthy individuals (234 men and 146 women; mean age 59.0 ±12.9 years) with a negative family history of cancer and residing in the region of Szczecin, Poland. These subjects were part of a population-based study of 1.3 million inhabitants of the West Pomerania province. The study was designed to identify familial aggregations of cancer and was performed by the International Hereditary Cancer Center, Department of Genetics and Pathology, Szczecin, Poland. Controls were matched to cases by age and sex.
Tumor classification The stage and histological type of GC were assessed by a routine histopathological examination. Histological types were classified according to the Lauren classification system. 24 The UICC TNM classification for malignant tumors was used for GC staging. Early GC was defined as invasive cancer that invaded no deeper than the submucosa, irrespective of lymph node metastasis. Tumor stage was defined as advanced in patients who had not undergone surgery or who presented with distal metastases or tumor infiltration confirmed by diagnostic procedures. Tumor location was classified as proximal (cardiac region) or other (truncus, antrum). Cases with complete stomach involvement were classified as having undetermined primary localization.
BRCA2 C5972T variant analysis A BRCA2 polymorphism analysis was performed at the International Hereditary Cancer Center, Department of Genetics and Pathology, Szczecin, Poland. The common BRCA2 variant (Thr1915Met) was analyzed in 380 patients with GC and 380 controls by the polymerase chain reaction-restriction fragments genes including OGG1 (8-oxoguanine DNA glycosylase), XRCC1 (X-ray repair cross-complementing protein 1), and BRCA2 (breast cancer 2) may increase or reduce the risk of cancer at various sites. Dong et al. 5 reviewed the results of meta-analyses and pooled analyses examining the role of candidate gene polymorphisms in genetic susceptibility to cancer. A positive relationship was evident between genetic variants and cancer risk including an association between MTH-FR (methylenetetrahydrofolate reductase) C677T variants and GC. Moreover, authors from Spain and Turkey confirmed the role of selected gene variants in gastric carcinogenesis in their countries. 6, 7 Particularly in Asian populations, an increased risk of GC development has been attributed to the genetic variants of just 2 repair genes, XRCC1 and XRCC3. [8] [9] [10] [11] However, other studies performed in Brazilian, Chinese, Italian, and Polish populations have failed to find such an association. [12] [13] [14] [15] Therefore, the relationship between the most commonly studied repair gene variants and GC is not entirely clear.
Less attention has been paid to the BRCA2 gene mutation and its variants in gastric carcinogenesis even though indirect family-based studies have reported an increased risk for GC in families carrying BRCA2 mutations. 16, 17 Jakubowska et al. 18 confirmed that the BRCA2 gene mutation is associated with familial aggregations of both breast cancer and GC in the Polish population. Similarly, our previous report on families with ovarian cancer and GC suggested that GC is part of the spectrum of cancers linked to BRCA2 gene mutations. 19 Still, a role of BRCA2 variants in gastric carcinogenesis has not been fully clarified despite the evidence that common BRCA2 human polymorphisms confer an increased risk of breast and ovarian cancers.
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The BRCA2 gene is located on the long (q) arm of chromosome 13 at position 12.3 and encodes a tumor suppressor protein which helps repair damaged DNA and ensures stability of cellular genetic material. Even a single amino acid substitution resulting from a polymorphism might be pathogenic to genome integrity. Given the proven link between BRCA2 germline mutations and GC risk in families with a history of breast and ovarian cancers as well as considering the role of BRCA2 polymorphisms in breast and ovarian cancer development, it would be valuable to establish whether BRCA2 nonsense mutations are also related to gastric carcinogenesis. This is a reasonable supposition because more than one-sixth of the patients in our GC group with a positive family history of cancer reported breast or ovarian cancers in close family relatives.
The purpose of this study was to examine a correlation between the BRCA2 C5972T common polymorphism, recognized as being associated with an increased risk of early-onset breast cancer in Poland and GC, by examining the prevalence of the BRCA2 variant in GC patients compared with controls. 23 We also searched for any stage (early vs advanced) of disease (n = 327) had early GC. The most common blood group in GC cases was group A (35.6%), followed by group O (34.9%), group B (19.0%), and group AB (10.5% Four cases with the BRCA2 C5972T variant and early GC were further evaluated by colonoscopy, gynecological ultrasound, and mammography. Two of those cases presented other neoplasms or potentially preneoplastic lesions. In 1 case, a tumor in the periuterum region was diagnosed. The second case was diagnosed with multiple colon polyps.
TABLE 2 shows overall ORs between carriers and noncarriers of the BRCA2 variant for gastric, breast, and ovarian cancers depending on family penetrance and the type of cancer. We observed a trend for an increased risk for breast and ovarian cancers in families testing positive for the polymorphism (OR, 2.51; 95% CI, 0.80-7.88; P = 0.11) but there was no risk of increase in GC (OR, 0.28; 95% CI, 0.04-2.16; P = 0.33).
DISCUSSION
The current study suggests a possible link between the BRCA2 C5972T common variant and GC development in the Polish population as well as a role of this variant in breast and ovarian carcinogenesis. The BRCA2 C5972T length polymorphism (PCR-RFLP) assay using primers b5972F (5'-CTC TCT AGA TAA TGA TGA ATG ATG CA) and b5972R (5'-CCA AAC TAA CAT CAC AAG GTG). The forward primer introduces an artificial restriction site for the Mph1103I enzyme (Fermentas, St. Leon-Rot, Germany).
Helicobacter pylori test Helicobacter pylori (H. pylori) status was tested using the rapid urease test (GOLD Hpdry, Grupo Bios, Chile). The H. pylori test was regarded as reliable only in patients who were not treated with antimicrobial agents or antisecretory drugs or 2 weeks after stopping such treatment.
Four patients after a previous successful eradication therapy, which had been administered no longer than for 2 to 3 months before the diagnosis of GC, were included into the H. pylori-positive group. The eradication treatment was applied because of the endoscopic view suggesting uncomplicated peptic ulcer disease.
Statistical analysis For statistical analysis, we used the χ² or Fisher exact test for categorical variables, and t test and Mann-Whitney test for continuous variables. A P value of less than 0.05 was considered statistically significant. All statistical analyses were performed with the statistical software package STATISTICA 10. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated from 2-by-2 tables.
GC patients were compared to the control group according to the frequency of the tested polymorphism. GC patients with the BRCA2 C5972T common variant were compared with GC patients-noncarriers with respect to selected clinical and pathological data. The family history of BRCA2 C5972T allele carriers was investigated more thoroughly to estimate the risk of gastric, breast, and ovarian cancers in the firstand second-degree relatives of those patients.
RESULTS
The baseline characteristics of GC patients are shown in TABLE 1. The median duration of symptoms was 6 months (range, 0-480 months). A surgery was performed in 244 patients, and the remainder underwent an exploratory surgery or were treated nonsurgically because of advanced GC or general contraindications. In 22.9% of all 353 cases with a well-defined site of cancer, a tumor was located in the proximal stomach. In the remaining 77.1% of the cases, the tumor site was classified as "other". In 27 cases, the entire stomach was involved or the tumor was located in the anastomosis from previous operations to treat ulcers; therefore, primary localization was not clear and could not be defined as either proximal or other. The primary histological type of the observed GC was diffuse (45.6%), followed by intestinal (44.9%) and mixed (9.5%). The most common stage of disease, according to the TNM classification, was stage IV (35.3%), followed by stage III (27.0%), stage II (20.7%), and stage I (17.0%). Fifty-nine patients with GC (18%) and a known diagnosed with ovarian cancer, with 42 of those patients reporting a family history of cancer. They identified 8 individuals carrying a common mutation (6174delT ) of the BRCA2 gene and 3 of them (37%) had stomach cancer. The authors suggested that the BRCA2 6174delT mutation predisposed patients to various cancers, among others, to GC. These findings were supported by other reports suggesting that BRCA2 mutations are likely to be the molecular basis for stomach cancer, but a direct relationship between BRCA2 silent allele variants and GC development has not been examined. [16] [17] [18] [19] Such an association is feasible on the basis of reports documenting the relationship between BRCA2 polymorphisms and breast and ovarian cancers as well as considering the polymorphism was observed in 28 patients with GC (7.4%) and in 18 controls (4.7%) (P = 0.17). Although the difference was not significant, the percentage of BRCA2 allele carriers in the GC group was almost twice higher that in controls and may indicate an increased risk for GC in BRCA2 polymorphism carriers.
To the best of our knowledge, there are no direct data linking any BRCA2 polymorphism with GC. A single study from Israel 25 examined 35 GC patients and found 2 patients (5.7%) carrying the 6174delT BRCA2 mutation. The authors concluded that BRCA2 germline mutations may contribute to GC genetic susceptibility in Jewish individuals. Berman et al. 26 analyzed DNA from 83 patients diagnosed with breast cancer and 93 factors, perhaps including the variant BRCA2 allele. Secondly, although there were no statistical differences between GC patient C5972T carriers and noncarriers in terms of histology, 50% of the carriers were diagnosed with diffuse GC. This was a surprising finding because none of the BRCA2 variant carriers in our study with diffuse GC had a positive family history of GC. Future studies will require larger populations with a family history of cancer to fully examine the incidence of diffuse GC. It has been suggested that HDGC is caused by a germline mutation in the CDH1 gene. 3, 27, 28 However, a study has documented that the CDH1 gene mutation is not present in Polish families that meet HDGC criteria. 29 Thus, other genetic factors may play a more important role in the development of HDGC in Polish families. The limitation of our study is its retrospective design, which resulted in the lack of selected data. Although the H. pylori status was not significantly different between individual cases with and without the BRCA2 polymorphism, it should be underlined that the H. pylori status was known only in 44.5% of the patients. What is more, according to the current recommendations, H. pylori tests should be performed at least 4 weeks after antibiotic therapy was completed. The time of 2 weeks before the H. pylori test adopted in our study could have affected the results of the infection status in our patients.
Considering these data, the relationship between the infection of H. pylori and genetic factors cannot be clearly assessed. It is possible that DNA alterations may be involved in the early stages of environmental carcinogenesis.
In conclusion, our study conducted on the Polish population suggests that GC may arise from a genetic background related to the BRCA2 C5972T common polymorphism and indicates a possible role of the variant allele in the development of breast and ovarian cancers. These observations will require further research to fully relationship between an increased risk of GC and polymorphisms in other DNA repair genes. [6] [7] [8] [9] [10] [11] [20] [21] [22] [23] Our study suggests that the BRCA2 C5972T variant is possibly involved in breast and ovarian carcinogenesis. We observed a trend towards an increased risk for breast and ovarian cancers in GC patient families carrying the variant allele. Similarly, a trend for an increased risk for developing either cancer was also observed in those families when the incidence of each cancer was analyzed separately (TABLE 2): breast cancer (OR, 2.23; 95% CI, 0.62-8.07; P = 0.19) and ovarian cancer (OR, 4.02; 95% CI, 0.45-36.27; P = 0.26). A trend for an increased risk in variant carriers is confirmed by the finding that 2 GC patients positive for the BRCA2 common variant were diagnosed with other metachronous cancers (in the first patient, ovarian and skin cancers, and in the second, breast cancer). These observations are in accordance with previous data from Górski et al., 23 who studied 3241 Polish breast cancer patients and controls and showed an association between the BRCA2 C5972T silent mutation and breast cancer, particularly in women younger than 40 years (OR, 1.4; 95% CI, 1.0-1.9; P = 0.04). If the relationship between an increased incidence of breast and ovarian cancers in families of GC patients carrying the BRCA2 variant was verified, it would be useful in genetic screening for both cancers in the families of GC patients. However, our results showed no evidence of an increased risk for GC in families carrying the variant allele.
Although we only found a trend for an increased risk for GC in BRCA2 C5972T allele carriers, 2 observations are noteworthy. First, the youngest GC patient among the 28 BRCA2 variant carriers was a 15-year-old woman without a positive family history of cancer. Taking into account her young age at diagnosis and the time required for cancer growth, it may be assumed that this case was not likely the result of environmental agents but was rather caused by genetic 
